About Septerna
Septerna is a company based in San Bruno (United States) founded in 2020. Septerna has raised $250 million across 2 funding rounds from investors including Mirae Asset, RA Capital and Driehaus. The company has 75 employees. Septerna offers products and services including Native Complex Platform and Oral Small Molecule Pipeline. Septerna operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Aclaris Therapeutics, Neurocrine and PTC Therapeutics, among others.
- Headquarter San Bruno, United States
- Employees 75
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website septerna.com
- Social LinkedIn X
- Legal Name Septerna, Inc.
- Annual Revenue$45.95 M (USD)4174.51as on Dec 31, 2025
- Net Profit-$48.88 M (USD)31.92as on Dec 31, 2025
- EBITDA-$79.19 M (USD)0.29as on Dec 31, 2025
- Total Equity Funding$250M (USD)
in 2 rounds
- Latest Funding Round$150M (USD), Series B
Jul 2023
- InvestorsMirae Asset
& 14 more
- Employee Count75
Products & Services of Septerna
Septerna offers a comprehensive portfolio of products and services, including Native Complex Platform and Oral Small Molecule Pipeline.
Industrial-scale platform for optimizing GPCR drug candidates.
Programs targeting endocrinology and metabolic diseases.
Funding Insights of Septerna
Septerna has successfully raised a total of $250M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $150 million completed in July 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $250M
- Total Rounds 2
- Last Round Series B — $150M
- First Round $100M
(Jan 2022)
- Investors Count 15
All 2 funding rounds of Septerna with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2023 | $150M | Series B | – | RA Capital Management | |
| Jan 2022 | $100M | Series A | – | Third Rock Ventures |
15 investors in total: 15 institutional.
Investors in Septerna
Septerna has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Mirae Asset, RA Capital and Driehaus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital funding is provided to early-stage life science companies. | – | thirdrockventures.com | Boston, United States | |
Venture capital funding is provided by Samsara BioCapital in California. | – | samsaracap.com | Palo Alto, United States | |
Long-term private equity investments in transformational opportunities are pursued. | – | invus.com | New York, United States | |
Venture capital is provided to biomedical technology startups. | – | cataliocapital.com | New York, United States | |
US private equity investments are managed by BVF Partners. | – | bvflp.com | San Francisco, United States | |
Investing in Life Sciences sectors like Healthcare and Biotechnology. | – | casdincapital.com | - | |
Private equity fund focused on the biotechnology sector | – | logoscapital.com | San Francisco, United States | |
Deep Track Capital is engaged in biotechnology investment activities. | – | deeptrackcapital.com | Greenwich, United States | |
- | – | vertexventureshc.com | - | |
- | – | soleuscapital.com | - |
Investor details for Septerna
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Septerna
58 people are tracked at Septerna (28 in leadership, 9 in board & advisors, 21 in team); the tracked headcount is 75.
| Name | Role | Group |
|---|---|---|
Antonij Tjahjadi | Senior Director Of Accounting | Leadership |
Alan Ezekowitz | Interim Chief Medical Officer | Leadership |
Matt Holdren | Vice President, Head Of Early Development | Leadership |
Heather Byers | Senior Medical Director | Leadership |
Jeffrey Finer | CEO & Co-Founder | Leadership |
Liz Bhatt | President & Chief Operating Officer | Leadership |
Samira Shaikhly | Chief People Officer | Leadership |
Uwe Klein | VP, Biological Sciences | Leadership |
Amer M. Mirza | VP, Disease Biology & Translational Sciences | Leadership |
Jun Zhang | Senior Director/project Team Lead, Disease Biology | Leadership |
Ran Xiao | Vp, Finance And Business Operations | Leadership |
Ali Masoudi | Co-founder & Associate Director | Leadership |
Mel M. | Director | Leadership |
Jasleen Sodhi | Director | Leadership |
Ken Eng | Senior Director, Talent Acquisition | Leadership |
David Lau | Vice President, Dmpk/clinical Pharmacology | Leadership |
Annemarie Lekkerkerker | Director Translational Sciences | Leadership |
Mabel Lee | Head Of Program And Portfolio Management | Leadership |
Jae B. Kim | Chief Medical Officer | Leadership |
Kate Pettrone Morse | Vice President, Commercial Strategy | Leadership |
38 more people are available in the full profile.
Complete people profiles for Septerna
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Septerna
Septerna is a publicly listed company on the NASDAQ with ticker symbol SEPN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date25 Oct 2024
- Listed onNASDAQ: SEPN
- Listed entitySepterna, Inc.
- Exchange sectorHealth technology
- ISINUS81734D1046
- Share price$38.37 (+3.98% on the day) · 2026-10-09
- Market capitalisation$1.79B
- EPS (diluted, trailing year)$-0.54
- Volume (last session)349,482
Financials of Septerna
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $46.0M | -$48.9M | -$79.2M |
| 2024 | $1.1M | -$71.8M | -$79.4M |
| 2023 | $151,000 | $567,000 | -$44.7M |
| 2022 | – | -$27.7M | -$27.4M |
Detailed financial statements for Septerna
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Septerna
4 dated milestones of Septerna across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Septerna is founded.
- Funding First funding round of $100.0M.
- Funding Latest funding round, Series B, of $150.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Septerna
Septerna operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Aclaris Therapeutics, Neurocrine and PTC Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| aclaristx.com | 2012 | Malvern, United States | $82M | 180 | Novel dermatologic therapies are developed for skin conditions. | |
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders | |
| ptcbio.com | 1998 | South Plainfield, United States | $248.1M | 995 | Small molecule drugs for rare diseases are developed. | |
| biohavenpharma.com | 2014 | New Haven, United States | $84.1M | 932 | Therapies for neurological and neuropsychiatric diseases are developed. | |
| escientpharma.com | 2017 | San Diego, United States | $237.5M | 44 | Small molecule therapeutics for inflammatory diseases are developed. | |
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. |
Detailed competitors of Septerna
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Septerna
The website of Septerna (septerna.com) receives about 11.6K visits a month and ranks #2,018,698 among all websites worldwide, #2,751 in Biotechnology and Pharmaceuticals.
- Monthly visits11.6K
▲ 12.4% vs previous month
- Unique visitors3.8K
per month
- Global rank#2,018,698
among all websites
- Category rank#2,751
Health · Biotechnology and Pharmaceuticals
- Bounce rate36%
- Pages per visit2.5
- Average visit1 min 22 sec
- DevicesDesktop 56% · Mobile 44%
Latest news on Septerna
Complete news archive for Septerna
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Septerna
10 companies that operate in the same segment as Septerna (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Septerna
Septerna was founded in 2020 and raised its 1st funding round 2 years after it was founded.
Septerna is headquartered in San Bruno, United States. It is registered at San Bruno, California, United States.
Septerna is a funded company, having raised a total of $250M across 2 funding rounds to date. The company's 1st funding round was a Series A of $100M, raised on Jan 2022.
Septerna has 75 employees.
Annual revenue of Septerna is $45.95M as on Dec 31, 2025.
Septerna was founded in 2020 and is based in San Bruno, United States. A GPCR-targeted drug discovery platform is operated, integrating biochemical, structural, and computational methods. The Native Complex platform is utilized to identify small molecules for disorders in endocrinology, central nervous system, metabolism, and inflammation. Focus is placed on advancing therapies through these combined approaches in the biotechnology sector.
Septerna's top competitors include Jazz Pharmaceuticals, Escient Pharmaceuticals and PTC Therapeutics.
Septerna offers Native Complex Platform and Oral Small Molecule Pipeline.
Yes, Septerna is publicly traded on NASDAQ under the ticker symbol SEPN.
Septerna has 15 investors. Key investors include Mirae Asset, RA Capital, Driehaus, Goldman Sachs Asset Management, and Third Rock Ventures.
Septerna operates through Septerna Corporation.